Objective In the European Union ~ 200.000 men will be diagnosed with prostate cancer and that number is likely to increase due to the aging population. If the disease is truly localized, patients can be cured by radical local treatment. However, if the malignant process has locally or distantly spread, no curative medical intervention is currently available.Since the early 1940-ties hormonal therapy has been the main stay in an attempt to control prostate neoplasms, but unfortunately this is only of palliative nature and tumour progression due to the expansive growth of cancer cells that are unresponsive to the currently available hormone therapies is inevitable. Prostate cancer has a strong tendency to spread to the bone, hence in order to combat the disease we have to explore the pathways that lead to hormone therapy unresponsive bone metastatic disease.It has become clear that in the majority of advanced prostate cancers the androgen receptor signalling pathway is active even in the absence of androgens. EC research teams have a leading role in AR research and will integrate their efforts to exploit androgen receptor mediated signalling as a therapeutic target. These teams will join forces with investigators that study the interaction between prostate cancer cells and the bone micro-environment. The exploration of the pathways leading to hormone therapy unresponsive bone metastatic disease will use functional genomics and expression profiling as technology platforms.These will also be used to identify new targets. This will ultimately lead to the establishment of assays to identify new (lead) compounds. These new drugs can be tested for their efficacy in models for bone metastatic prostate cancer; hence translation of our knowledge into therapeutic strategies will also be integrated in this consortium to effectively combat prostate cancer. Fields of science medical and health sciencesclinical medicineoncologyprostate cancernatural sciencesbiological sciencesgenetics Keywords androgen receoptor bone metastasis immuno therapy prostate cancer Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2002-2.2.0-2 - Multidisciplinary research to explore and validate molecular targets for innovative treatment Call for proposal FP6-2002-LIFESCIHEALTH See other projects for this call Funding Scheme IP - Integrated Project Coordinator STICHTING KATHOLIEKE UNIVERSITEIT Address Geert grooteplein-zuid 10 Nijmegen Netherlands See on map Links Website Opens in new window EU contribution € 0,00 Participants (16) Sort alphabetically Sort by EU Contribution Expand all Collapse all CENTRE DE RECHERCHE POUR LES PATHOLOGIES PROSTATIQUES France EU contribution € 0,00 Address Rue de capitaine feber, 60 Paris See on map CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET EN MEDICINE (GIE) France EU contribution € 0,00 Address 1 rue laurent fries Illkirch See on map Links Website Opens in new window COMPOUND HANDLING B.V. Netherlands EU contribution € 0,00 Address Kluyverweg 6 Delft See on map Links Website Opens in new window ERASMUS MEDICAL CENTRE Netherlands EU contribution € 0,00 Address Dr. molewaterplein 40 Rotterdam See on map Links Website Opens in new window FORSCHUNGSZENTRUM KARLSRUHE GMBH Germany EU contribution € 0,00 Address Weberstrasse 5 Karlsruhe See on map Links Website Opens in new window LEIDEN UNIVERSITY MEDICAL CENTRE Netherlands EU contribution € 0,00 Address Albinusdreef 2 Leiden See on map Links Website Opens in new window MEDIZINISCHE UNIVERSITÄT INNSBRUCK Austria EU contribution € 0,00 Address Innrain 52 Innsbruck See on map Links Website Opens in new window SPECIALITY CHEMICAL SERVICES HOLDING B.V. Netherlands EU contribution € 0,00 Address Delftechpark 30 Delft See on map Links Website Opens in new window THE CHANCELLORS MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE United Kingdom EU contribution € 0,00 Address The old schools, trinity lane Cambridge See on map Links Website Opens in new window UNIVERSITY OF BERN Switzerland EU contribution € 0,00 Address Hochschulstrasse 4 Bern See on map Links Website Opens in new window UNIVERSITY OF NEWCASTLE UPON TYNE United Kingdom EU contribution € 0,00 Address 6 kensington terrace Newcastle upon tyne See on map Links Website Opens in new window UNIVERSITY OF SHEFFIELD United Kingdom EU contribution € 0,00 Address Firth court, western bank Sheffield See on map Links Website Opens in new window UNIVERSITY OF TAMPERE Finland EU contribution € 0,00 Address Kalevantie 4 Tampere See on map Links Website Opens in new window UNIVERSITY OF TURKU Finland EU contribution € 0,00 Address Itainen pitkakatu 4a Turku See on map Links Website Opens in new window UNIVERSITY OF YORK United Kingdom EU contribution € 0,00 Address Heslington York See on map Links Website Opens in new window WEIZMANN INSTITUTE OF SCIENCE Israel EU contribution € 0,00 Address Herzl street Rehovot See on map Links Website Opens in new window